Objective: Our study aimed to elucidate the presence, antigen specificities, and potential clinical association of anti-neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphospholipid antibody (aPL)-positive patients who did not have lupus. Methods: Anti-NET IgG/IgM were measured in sera of 389 aPL-positive patients; 308 met the classification criteria for APS. Multivariate logistic regression with best variable model selection was used to determine clinical associations. For a subset of the patients (n=214), we profiled autoantibodies with an autoantigen microarray platform. Results: We found elevated levels of anti-NET IgG and/or IgM in 45% of aPL-positive patients. High anti-NET antibody levels are associated with more circulating myeloperoxidase (MPO)-DNA complexes, a biomarker of NETs. When considering clinical manifestations, positive anti-NET IgG was associated with brain white matter lesions even after adjusting for demographic variables and aPL profiles. Anti-NET IgM tracked with complement consumption after controlling for aPL profiles; furthermore, patient serum containing high levels of anti-NET IgM efficiently deposited complement C3d on NETs. As determined by autoantigen microarray, positive testing for anti-NET IgG was significantly associated with several autoantibodies, including those recognizing citrullinated histones, heparan sulfate proteoglycan, laminin, MPO-DNA complexes, and nucleosomes. Anti-NET IgM positivity associated with autoantibodies targeting single-stranded DNA, double-stranded DNA, and proliferating cell nuclear antigen. Conclusion: These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, anti-NET IgG species appear more likely to target NET-associated protein antigens. This article is protected by copyright. All rights reserved.

Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository / Zuo, Yu; Navaz, Sherwin; Tsodikov, Alex; Kmetova, Katarina; Kluge, Lyndsay; Ambati, Amala; K Hoy, Claire; Yalavarthi, Srilakshmi; de Andrade, Danieli; G Tektonidou, Maria; Sciascia, Savino; Pengo, Vittorio; Ruiz-Irastorza, Guillermo; Michael Belmont, H; Gerosa, Maria; R Fortin, Paul; Ramires de Jesus, Guilherme; Ware Branch, D; Andreoli, Laura; Rodriguez-Almaraz, Esther; Petri, Michelle; Cervera, Ricard; Willis, Rohan; R Karp, David; Li, Quan-Zhen; Cohen, Hannah; Laura Bertolaccini, Maria; Erkan, Doruk; S Knight, Jason; Barilaro, Giuseppe. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5205. - (2023). [10.1002/art.42489]

Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository

Giuseppe Barilaro
2023

Abstract

Objective: Our study aimed to elucidate the presence, antigen specificities, and potential clinical association of anti-neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphospholipid antibody (aPL)-positive patients who did not have lupus. Methods: Anti-NET IgG/IgM were measured in sera of 389 aPL-positive patients; 308 met the classification criteria for APS. Multivariate logistic regression with best variable model selection was used to determine clinical associations. For a subset of the patients (n=214), we profiled autoantibodies with an autoantigen microarray platform. Results: We found elevated levels of anti-NET IgG and/or IgM in 45% of aPL-positive patients. High anti-NET antibody levels are associated with more circulating myeloperoxidase (MPO)-DNA complexes, a biomarker of NETs. When considering clinical manifestations, positive anti-NET IgG was associated with brain white matter lesions even after adjusting for demographic variables and aPL profiles. Anti-NET IgM tracked with complement consumption after controlling for aPL profiles; furthermore, patient serum containing high levels of anti-NET IgM efficiently deposited complement C3d on NETs. As determined by autoantigen microarray, positive testing for anti-NET IgG was significantly associated with several autoantibodies, including those recognizing citrullinated histones, heparan sulfate proteoglycan, laminin, MPO-DNA complexes, and nucleosomes. Anti-NET IgM positivity associated with autoantibodies targeting single-stranded DNA, double-stranded DNA, and proliferating cell nuclear antigen. Conclusion: These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, anti-NET IgG species appear more likely to target NET-associated protein antigens. This article is protected by copyright. All rights reserved.
2023
Anti-NET antibodies
01 Pubblicazione su rivista::01a Articolo in rivista
Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository / Zuo, Yu; Navaz, Sherwin; Tsodikov, Alex; Kmetova, Katarina; Kluge, Lyndsay; Ambati, Amala; K Hoy, Claire; Yalavarthi, Srilakshmi; de Andrade, Danieli; G Tektonidou, Maria; Sciascia, Savino; Pengo, Vittorio; Ruiz-Irastorza, Guillermo; Michael Belmont, H; Gerosa, Maria; R Fortin, Paul; Ramires de Jesus, Guilherme; Ware Branch, D; Andreoli, Laura; Rodriguez-Almaraz, Esther; Petri, Michelle; Cervera, Ricard; Willis, Rohan; R Karp, David; Li, Quan-Zhen; Cohen, Hannah; Laura Bertolaccini, Maria; Erkan, Doruk; S Knight, Jason; Barilaro, Giuseppe. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5205. - (2023). [10.1002/art.42489]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1675607
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 9
social impact